BeOne Medicines Forecast, price target & analysts
BeOne Medicines Target price 2026 - Analyst rating & recommendation
BeOne Medicines Classifications & Recommendation
BeOne Medicines Price Target
| Target Price | CN¥369.84 |
| Price | CN¥264.41 |
| Potential |
39.87%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target BeOne Medicines 2027 .
The average BeOne Medicines target price is CN¥369.84.
This is
39.87%
register free of charge
CN¥476.81
80.33%
register free of charge
CN¥308.66
16.73%
register free of charge
|
|
| A rating was issued by 12 analysts: 11 Analysts recommend BeOne Medicines to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BeOne Medicines stock has an average upside potential 2027 of
39.87%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion CN¥ | 38.23 | 47.04 |
| 40.46% | 23.06% | |
| EBITDA Margin | 9.23% | 18.34% |
| 168.74% | 98.60% | |
| Net Margin | 3.82% | 12.89% |
| 120.89% | 237.32% |
7 Analysts have issued a sales forecast BeOne Medicines 2026 . The average BeOne Medicines sales estimate is
This results in the following potential growth metrics:
7 BeOne Medicines Analysts have issued a net profit forecast 2026. The average BeOne Medicines net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CN¥ | 0.98 | 4.13 |
| 126.92% | 321.43% | |
| P/E | 64.10 | |
| EV/Sales | 5.44 |
7 Analysts have issued a BeOne Medicines forecast for earnings per share. The average BeOne Medicines EPS is
This results in the following potential growth metrics and future valuations:
BeOne Medicines...
Current BeOne Medicines Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 18 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| Citizens |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 20 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Oct 08 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 18 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 18 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
Citizens:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 20 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 08 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 18 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
